Sage Spurns Biogen, Turns Attention To Strategic Review
Proposed Deal’s Value Seen As Too Low
Sage’s board of directors initiated a search for strategic alternatives, which could include a sale of the company, but the board rejected a buyout bid from Biogen, its partner on the PPD drug Zurzuvae.
